Loading…
Etamycin as a Novel Mycobacterium abscessus Inhibitor
The increase in drug-resistant , which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against . We found that etamycin significantly inhibited the...
Saved in:
| Published in: | International journal of molecular sciences 2020-09, Vol.21 (18), p.6908 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4088-8a7a5bd570605c2533768fbd4ac99552e7324fcaa8d87c0e29509e9ad70df75c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4088-8a7a5bd570605c2533768fbd4ac99552e7324fcaa8d87c0e29509e9ad70df75c3 |
| container_end_page | |
| container_issue | 18 |
| container_start_page | 6908 |
| container_title | International journal of molecular sciences |
| container_volume | 21 |
| creator | Hanh, Bui Thi Bich Kim, Tae Ho Park, June-Woo Lee, Da-Gyum Kim, Jae-Sung Du, Young Eun Yang, Chul-Su Oh, Dong-Chan Jang, Jichan |
| description | The increase in drug-resistant
, which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against
. We found that etamycin significantly inhibited the growth of
wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of
that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish (
) infection model was greater than that of clarithromycin, which is recommended as the core agent for treating
infections. Thus, we concluded that etamycin is a potential anti-
candidate for further development as a clinical drug candidate. |
| doi_str_mv | 10.3390/ijms21186908 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5820f38eacf74c2ba3f2e06b031149c5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5820f38eacf74c2ba3f2e06b031149c5</doaj_id><sourcerecordid>32967077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4088-8a7a5bd570605c2533768fbd4ac99552e7324fcaa8d87c0e29509e9ad70df75c3</originalsourceid><addsrcrecordid>eNpVkcFOwzAMhiMEYmNw44z6ABTcpGmSCxJCAyYNuMA5ctN0y9QuU9JN2ttTGEzbyZb9-7Pln5DrDO4YU3DvFm2kWSYLBfKEDLOc0hSgEKcH-YBcxLgAoIxydU4GjKpCgBBDwscdtlvjlgnGBJN3v7FN8rY1vkTT2eDWbYJlNDbGdUwmy7krXefDJTmrsYn26i-OyNfz-PPpNZ1-vEyeHqepyUHKVKJAXlZcQAHcUM6YKGRdVjkapTinVjCa1wZRVlIYsFRxUFZhJaCqBTdsRCY7buVxoVfBtRi22qPTvwUfZhpD50xjNZcUaiYtmlrkhpbIamqhKIFlWa4M71kPO9ZqXba2MnbZBWyOoMedpZvrmd9owftTpegBtzuACT7GYOv9bAb6xwp9aEUvvznctxf__559A2h2hSg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Etamycin as a Novel Mycobacterium abscessus Inhibitor</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Hanh, Bui Thi Bich ; Kim, Tae Ho ; Park, June-Woo ; Lee, Da-Gyum ; Kim, Jae-Sung ; Du, Young Eun ; Yang, Chul-Su ; Oh, Dong-Chan ; Jang, Jichan</creator><creatorcontrib>Hanh, Bui Thi Bich ; Kim, Tae Ho ; Park, June-Woo ; Lee, Da-Gyum ; Kim, Jae-Sung ; Du, Young Eun ; Yang, Chul-Su ; Oh, Dong-Chan ; Jang, Jichan</creatorcontrib><description>The increase in drug-resistant
, which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against
. We found that etamycin significantly inhibited the growth of
wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of
that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish (
) infection model was greater than that of clarithromycin, which is recommended as the core agent for treating
infections. Thus, we concluded that etamycin is a potential anti-
candidate for further development as a clinical drug candidate.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21186908</identifier><identifier>PMID: 32967077</identifier><language>eng</language><publisher>Switzerland: MDPI</publisher><subject>Animals ; drug resistance ; Female ; Fish Diseases - drug therapy ; Fish Diseases - microbiology ; Macrolides - pharmacology ; Mice ; Mycobacterium abscessus ; Mycobacterium abscessus - growth & development ; Mycobacterium Infections, Nontuberculous - drug therapy ; novel drug discovery ; Zebrafish - microbiology</subject><ispartof>International journal of molecular sciences, 2020-09, Vol.21 (18), p.6908</ispartof><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4088-8a7a5bd570605c2533768fbd4ac99552e7324fcaa8d87c0e29509e9ad70df75c3</citedby><cites>FETCH-LOGICAL-c4088-8a7a5bd570605c2533768fbd4ac99552e7324fcaa8d87c0e29509e9ad70df75c3</cites><orcidid>0000-0003-3787-6455 ; 0000-0003-4918-961X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555287/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555287/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32967077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hanh, Bui Thi Bich</creatorcontrib><creatorcontrib>Kim, Tae Ho</creatorcontrib><creatorcontrib>Park, June-Woo</creatorcontrib><creatorcontrib>Lee, Da-Gyum</creatorcontrib><creatorcontrib>Kim, Jae-Sung</creatorcontrib><creatorcontrib>Du, Young Eun</creatorcontrib><creatorcontrib>Yang, Chul-Su</creatorcontrib><creatorcontrib>Oh, Dong-Chan</creatorcontrib><creatorcontrib>Jang, Jichan</creatorcontrib><title>Etamycin as a Novel Mycobacterium abscessus Inhibitor</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>The increase in drug-resistant
, which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against
. We found that etamycin significantly inhibited the growth of
wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of
that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish (
) infection model was greater than that of clarithromycin, which is recommended as the core agent for treating
infections. Thus, we concluded that etamycin is a potential anti-
candidate for further development as a clinical drug candidate.</description><subject>Animals</subject><subject>drug resistance</subject><subject>Female</subject><subject>Fish Diseases - drug therapy</subject><subject>Fish Diseases - microbiology</subject><subject>Macrolides - pharmacology</subject><subject>Mice</subject><subject>Mycobacterium abscessus</subject><subject>Mycobacterium abscessus - growth & development</subject><subject>Mycobacterium Infections, Nontuberculous - drug therapy</subject><subject>novel drug discovery</subject><subject>Zebrafish - microbiology</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkcFOwzAMhiMEYmNw44z6ABTcpGmSCxJCAyYNuMA5ctN0y9QuU9JN2ttTGEzbyZb9-7Pln5DrDO4YU3DvFm2kWSYLBfKEDLOc0hSgEKcH-YBcxLgAoIxydU4GjKpCgBBDwscdtlvjlgnGBJN3v7FN8rY1vkTT2eDWbYJlNDbGdUwmy7krXefDJTmrsYn26i-OyNfz-PPpNZ1-vEyeHqepyUHKVKJAXlZcQAHcUM6YKGRdVjkapTinVjCa1wZRVlIYsFRxUFZhJaCqBTdsRCY7buVxoVfBtRi22qPTvwUfZhpD50xjNZcUaiYtmlrkhpbIamqhKIFlWa4M71kPO9ZqXba2MnbZBWyOoMedpZvrmd9owftTpegBtzuACT7GYOv9bAb6xwp9aEUvvznctxf__559A2h2hSg</recordid><startdate>20200921</startdate><enddate>20200921</enddate><creator>Hanh, Bui Thi Bich</creator><creator>Kim, Tae Ho</creator><creator>Park, June-Woo</creator><creator>Lee, Da-Gyum</creator><creator>Kim, Jae-Sung</creator><creator>Du, Young Eun</creator><creator>Yang, Chul-Su</creator><creator>Oh, Dong-Chan</creator><creator>Jang, Jichan</creator><general>MDPI</general><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3787-6455</orcidid><orcidid>https://orcid.org/0000-0003-4918-961X</orcidid></search><sort><creationdate>20200921</creationdate><title>Etamycin as a Novel Mycobacterium abscessus Inhibitor</title><author>Hanh, Bui Thi Bich ; Kim, Tae Ho ; Park, June-Woo ; Lee, Da-Gyum ; Kim, Jae-Sung ; Du, Young Eun ; Yang, Chul-Su ; Oh, Dong-Chan ; Jang, Jichan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4088-8a7a5bd570605c2533768fbd4ac99552e7324fcaa8d87c0e29509e9ad70df75c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>drug resistance</topic><topic>Female</topic><topic>Fish Diseases - drug therapy</topic><topic>Fish Diseases - microbiology</topic><topic>Macrolides - pharmacology</topic><topic>Mice</topic><topic>Mycobacterium abscessus</topic><topic>Mycobacterium abscessus - growth & development</topic><topic>Mycobacterium Infections, Nontuberculous - drug therapy</topic><topic>novel drug discovery</topic><topic>Zebrafish - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hanh, Bui Thi Bich</creatorcontrib><creatorcontrib>Kim, Tae Ho</creatorcontrib><creatorcontrib>Park, June-Woo</creatorcontrib><creatorcontrib>Lee, Da-Gyum</creatorcontrib><creatorcontrib>Kim, Jae-Sung</creatorcontrib><creatorcontrib>Du, Young Eun</creatorcontrib><creatorcontrib>Yang, Chul-Su</creatorcontrib><creatorcontrib>Oh, Dong-Chan</creatorcontrib><creatorcontrib>Jang, Jichan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hanh, Bui Thi Bich</au><au>Kim, Tae Ho</au><au>Park, June-Woo</au><au>Lee, Da-Gyum</au><au>Kim, Jae-Sung</au><au>Du, Young Eun</au><au>Yang, Chul-Su</au><au>Oh, Dong-Chan</au><au>Jang, Jichan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etamycin as a Novel Mycobacterium abscessus Inhibitor</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2020-09-21</date><risdate>2020</risdate><volume>21</volume><issue>18</issue><spage>6908</spage><pages>6908-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>The increase in drug-resistant
, which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against
. We found that etamycin significantly inhibited the growth of
wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of
that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish (
) infection model was greater than that of clarithromycin, which is recommended as the core agent for treating
infections. Thus, we concluded that etamycin is a potential anti-
candidate for further development as a clinical drug candidate.</abstract><cop>Switzerland</cop><pub>MDPI</pub><pmid>32967077</pmid><doi>10.3390/ijms21186908</doi><orcidid>https://orcid.org/0000-0003-3787-6455</orcidid><orcidid>https://orcid.org/0000-0003-4918-961X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2020-09, Vol.21 (18), p.6908 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_5820f38eacf74c2ba3f2e06b031149c5 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Animals drug resistance Female Fish Diseases - drug therapy Fish Diseases - microbiology Macrolides - pharmacology Mice Mycobacterium abscessus Mycobacterium abscessus - growth & development Mycobacterium Infections, Nontuberculous - drug therapy novel drug discovery Zebrafish - microbiology |
| title | Etamycin as a Novel Mycobacterium abscessus Inhibitor |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A32%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etamycin%20as%20a%20Novel%20Mycobacterium%20abscessus%20Inhibitor&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Hanh,%20Bui%20Thi%20Bich&rft.date=2020-09-21&rft.volume=21&rft.issue=18&rft.spage=6908&rft.pages=6908-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21186908&rft_dat=%3Cpubmed_doaj_%3E32967077%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4088-8a7a5bd570605c2533768fbd4ac99552e7324fcaa8d87c0e29509e9ad70df75c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32967077&rfr_iscdi=true |